Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AC Immune (ACIU) EBITDA Margin: 2015-2025

Historic EBITDA Margin for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -1,692.55%.

  • AC Immune's EBITDA Margin fell 172173.00% to -1,692.55% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,659.88%, marking a year-over-year decrease of 152010.00%. This contributed to the annual value of -191.80% for FY2024, which is 17050.00% up from last year.
  • Latest data reveals that AC Immune reported EBITDA Margin of -1,692.55% as of Q3 2025, which was down 15.56% from -1,464.62% recorded in Q2 2025.
  • In the past 5 years, AC Immune's EBITDA Margin ranged from a high of 34,653.33% in Q2 2024 and a low of -503,550.00% during Q3 2021.
  • In the last 3 years, AC Immune's EBITDA Margin had a median value of -1,637.47% in 2024 and averaged 1,760.80%.
  • As far as peak fluctuations go, AC Immune's EBITDA Margin slumped by 50,188,508bps in 2021, and later surged by 50,320,844bps in 2022.
  • AC Immune's EBITDA Margin (Quarterly) stood at -30,193.33% in 2021, then soared by 2,543,583bps to -4,757.51% in 2022, then skyrocketed by 368,448bps to -1,073.03% in 2023, then tumbled by 56,444bps to -1,637.47% in 2024, then tumbled by 172,173bps to -1,692.55% in 2025.
  • Its last three reported values are -1,692.55% in Q3 2025, -1,464.62% for Q2 2025, and -1,931.21% during Q1 2025.